Logo image of ALCRB.PA

CARBIOS (ALCRB.PA) Stock Fundamental Analysis

EPA:ALCRB - Euronext Paris - Matif - FR0011648716 - Common Stock - Currency: EUR

8.625  +0.28 (+3.36%)

Fundamental Rating

3

Taking everything into account, ALCRB scores 3 out of 10 in our fundamental rating. ALCRB was compared to 68 industry peers in the Chemicals industry. The financial health of ALCRB is average, but there are quite some concerns on its profitability. ALCRB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALCRB had negative earnings in the past year.
In the past year ALCRB has reported a negative cash flow from operations.
ALCRB had negative earnings in 4 of the past 5 years.
In the past 5 years ALCRB always reported negative operating cash flow.
ALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of ALCRB (-11.83%) is worse than 77.94% of its industry peers.
Looking at the Return On Equity, with a value of -16.58%, ALCRB is doing worse than 73.53% of the companies in the same industry.
Industry RankSector Rank
ROA -11.83%
ROE -16.58%
ROIC N/A
ROA(3y)-11.97%
ROA(5y)-10.26%
ROE(3y)-16.77%
ROE(5y)-14.67%
ROIC(3y)N/A
ROIC(5y)N/A
ALCRB.PA Yearly ROA, ROE, ROICALCRB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

ALCRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCRB.PA Yearly Profit, Operating, Gross MarginsALCRB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

5

2. Health

2.1 Basic Checks

ALCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALCRB remains at a similar level compared to 1 year ago.
ALCRB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALCRB has remained at the same level compared to a year ago.
ALCRB.PA Yearly Shares OutstandingALCRB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALCRB.PA Yearly Total Debt VS Total AssetsALCRB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ALCRB has an Altman-Z score of 0.45. This is a bad value and indicates that ALCRB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.45, ALCRB is doing worse than 82.35% of the companies in the same industry.
ALCRB has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.18, ALCRB is doing good in the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z 0.45
ROIC/WACCN/A
WACC6.97%
ALCRB.PA Yearly LT Debt VS Equity VS FCFALCRB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ALCRB has a Current Ratio of 2.79. This indicates that ALCRB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.79, ALCRB belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
A Quick Ratio of 2.75 indicates that ALCRB has no problem at all paying its short term obligations.
ALCRB's Quick ratio of 2.75 is amongst the best of the industry. ALCRB outperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.75
ALCRB.PA Yearly Current Assets VS Current LiabilitesALCRB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ALCRB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.38%.
ALCRB shows a strong growth in Revenue. In the last year, the Revenue has grown by 466.67%.
The Revenue for ALCRB have been decreasing by -37.71% on average. This is quite bad
EPS 1Y (TTM)3.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)466.67%
Revenue growth 3Y9.01%
Revenue growth 5Y-37.71%
Sales Q2Q%1475%

3.2 Future

ALCRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.01% yearly.
The Revenue is expected to grow by 300.17% on average over the next years. This is a very strong growth
EPS Next Y1.82%
EPS Next 2Y8.12%
EPS Next 3Y6.49%
EPS Next 5Y27.01%
Revenue Next Year108.33%
Revenue Next 2Y400%
Revenue Next 3Y452.61%
Revenue Next 5Y300.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALCRB.PA Yearly Revenue VS EstimatesALCRB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ALCRB.PA Yearly EPS VS EstimatesALCRB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCRB. In the last year negative earnings were reported.
Also next year ALCRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCRB.PA Price Earnings VS Forward Price EarningsALCRB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCRB.PA Per share dataALCRB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.12%
EPS Next 3Y6.49%

More info and screens

0

5. Dividend

5.1 Amount

ALCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARBIOS

EPA:ALCRB (8/8/2025, 7:00:00 PM)

8.625

+0.28 (+3.36%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)04-11 2025-04-11/amc
Earnings (Next)09-23 2025-09-23
Inst Owners18.1%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap145.33M
Analysts83.64
Price Target11.9 (37.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-94.55%
Revenue NY rev (3m)-94.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1068.61
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-5.32
FCFYN/A
OCF(TTM)-1.79
OCFYN/A
SpS0.01
BVpS11.85
TBVpS9.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.83%
ROE -16.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-11.97%
ROA(5y)-10.26%
ROE(3y)-16.77%
ROE(5y)-14.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 732.56%
Cap/Sales 43678.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.75
Altman-Z 0.45
F-Score4
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)437.01%
Cap/Depr(5y)449.88%
Cap/Sales(3y)53289.6%
Cap/Sales(5y)34828.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y1.82%
EPS Next 2Y8.12%
EPS Next 3Y6.49%
EPS Next 5Y27.01%
Revenue 1Y (TTM)466.67%
Revenue growth 3Y9.01%
Revenue growth 5Y-37.71%
Sales Q2Q%1475%
Revenue Next Year108.33%
Revenue Next 2Y400%
Revenue Next 3Y452.61%
Revenue Next 5Y300.17%
EBIT growth 1Y-29.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.5%
EBIT Next 3Y20.82%
EBIT Next 5Y34.22%
FCF growth 1Y-91.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.67%
OCF growth 3YN/A
OCF growth 5YN/A